4H (hypomyelination, hypodontia and hypogonadotropic hypogonadism) leukodystrophy (4H) is an autosomal recessive hypomyelinating white matter (WM) disorder with neurologic, dental, and endocrine abnormalities. The aim of this study was to develop and validate a magnetic resonance imaging (MRI) scoring system for 4H. A scoring system (0-54) was developed to quantify hypomyelination and atrophy of different brain regions. Pons diameter and bicaudate ratio were included as measures of cerebral and brainstem atrophy, and reference values were determined using Ã The authors contributed equally to this work. ‡ The authors contributed equally to this work.
Introduction
Hypomyelinating disorders constitute a heterogeneous group of different disease entities, defined by a permanent and significant lack of central nervous system myelin. 1 One of the striking features of these conditions is the large variation in severity: some patients have virtually no neurologic signs and normal cognition, and others are severely affected early on and wheelchair-bound, usually with less profoundly affected cognitive function. A recent study aimed at correlating gross motor function (GMF) with quantitative white matter (WM) magnetic resonance imaging (MRI) parameters and showed that in a heterogeneous group of patients with hypomyelination, it is mainly the lack of myelin that codetermines motor handicap.
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Short of quantitative information, it is desirable to grade imaging severity tailored to a single hypomyelinating entity by assessing the degree of myelin deficit and atrophy using conventional T1-and T2-weighted images and to correlate these scores with GMF. This would be helpful for retrospective studies, as these images are available for most patients, as well as for routine clinical use, providing useful information for future therapeutic trials. Such scoring systems have proven to be a valuable tool for other leukodystrophies such as X-linked adrenoleukodystrophy (X-ALD) and metachromatic leukodystrophy (MLD). 3, 4 Recently, a scoring system for Pelizaeus-Merzbacher's disease (PMD), the most common hypomyelinating disorder, was published but was not available when we were embarking on this project.
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We aimed to develop a scoring system for a hypomyelinating disorder, 4H leukodystrophy (4H), the second most common hypomyelinating entity 6 characterized by hypomyelination, hypodontia, and hypogonadotropic hypogonadism. [7] [8] [9] Recessive mutations in either POLR3A, POLR3B
or POLR1C, encoding subunits of RNA polymerase III and I, cause almost all cases with the clinical diagnosis of 4H, with mutations in POLR3B explaining the majority of cases in Central and Western Europe and mutations in POLR1C being the least frequent. [10] [11] [12] [13] [14] Clinical variation is wide, ranging from mild, even subclinical ataxia, to severe motor handicap, and the course is, after a stable phase ranging from 2 to 3 years to more than 10 years, slowly progressive in most. In addition to hypomyelination, MRI findings comprise early cerebellar atrophy, especially in cases with mutations in POLR3B, and late, milder supratentorial brain atrophy including thinning of the corpus callosum.
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Some WM structures are better myelinated: the optic radiation, the ventrolateral thalamus, the pyramidal tract in the posterior limb of the internal capsule, the dentate nucleus, and the medial lemniscus in the brain stem. 16 We present a novel MRI rating scale that reflects these findings and determined its interrater reliability (IRR) and clinical validity.
Patients and Methods

Patient Selection
Brain MRI scans were retrospectively collected from patients with genetically proven 4H from the databases of VU Medical Center in Amsterdam, the Netherlands, and Montreal Children's Hospital in Montreal, Canada. Scans had been performed at different scanners (1.5 and 3T) following different protocols at different centers and were included when at least axial T2-and T1-weighted images and a sagittal series were available. Only patients with MRI scans acquired at 24 months of age or later were included because normal myelination is not completed before this age.
Controls
A total of 86 healthy individuals (45 males, 41 females) with a median age of 6.5 years (range: 0-29) served as a control group. We focused on younger ages as there were no good normal values for bicaudate ratio (BCR) and brainstem diameter available in contrast to adults. Reasons for MRI were headache, mild epilepsy without focal neurologic abnormalities, or mild developmental delay. All were evaluated by (pediatric) neurologists and radiologists, and no abnormal neurologic or MRI findings were identified.
Magnetic Resonance Imaging Scoring
We developed a scoring system to assess hypomyelination and atrophy of different brain regions (►Table 1). Hypomyelination was graded separately on axial T1-and T2-weighted images, depending on the signal intensity in relation to the caudate nucleus. Atrophy was visually scored for selected structures (cerebellum, corpus callosum; ►Fig. quantified using the BCR, defined as the smallest intercaudate distance divided by the transverse width of the inner table of the skull at the same level. These distances were measured on T2-weighted axial images with the smallest intercaudate distance (►Fig. 2C, D). Brainstem atrophy was quantified by measuring maximal anteroposterior diameter at the level of the midpons on sagittal images (►Fig. 2E). Overall, patients could receive a score between 0 and 44 for hypomyelination and between 0 and 10 for atrophy, adding up to a total score of 0 to 54, with higher scores corresponding to more severe abnormalities. Two neuroradiologists (F. B. and I. H.) and three pediatric neurologists (R. L. P., A. V., and G. B.), experienced in WM diseases, were asked to individually complete the scoring system for all patients. They were blinded to patient identifiers including age (the scores for the two age-dependent items, BCR and pons diameter, were deduced from the measurements the scorers provided). When three or more raters agreed on a score, this score was used for further analysis on clinical validity. Items for which less than three raters agreed on a score were sent for a second round of scoring to reach consensus. IRR was assessed for all individual MRI scoring items and measurements, as well as overall MRI severity scores, separately for the first and second rounds. Total MRI severity, hypomyelination, and atrophy scores were analyzed, including their association to factors such as age, gender, and mutated gene. For both pons diameter and BCR, agerelated reference ranges were determined using scans of controls with normal MRI.
Correlation to Gross Motor Function
Patients were retrospectively classified according to the GMF classification system (GMFCS) 17 based on clinical examination or clinical notes from the year in which the MRI study was performed. Retrospective estimation of GMF scores was previously shown to be reliable.
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Statistical Analysis
Data were analyzed by SPSS, version 20.0 for Windows (SPSS Inc., Chicago, IL), GraphPad Prism 7 (GraphPad Software, San Diego, CA), and R Software (R Foundation for statistical computing, Vienna, Austria). For determining reference ranges, normal values of BCR and pons diameter were plotted and, where appropriate, modeled by a (monotone) exponential curve fitted by means of nonlinear least squares. Subsequently, reference ranges were determined using population means and standard errors. IRR was expressed using the single measure intraclass correlation coefficient (ICC), which was analyzed by means of a two-way mixed model based on absolute agreement (for separate items) or consistency (for total scores). Cutoffs for ICC were derived from Cicchetti, with ICC values less than 0.40 being considered as poor, values between 0.40 and 0.59 as fair, values between 0.60 and 0.74 as good, and values between 0.75 and 1.00 as excellent.
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Pearson (r) and Spearman (ρ) correlations were computed to determine associations between age, GMF, and MRI variables including total MRI score, hypomyelination, and atrophy scores. Subgroup differences for gender, gene mutation, and age groups were tested using a general linear model, analysis of variance, and Mann-Whitney U test and associated p-values. P-values of 0.05 or less were considered significant. 
Results
Patients and Controls
A total of 40 MRI brain scans (32 on a 1.5T scanner, 8 on a 3T scanner) were collected from 36 (19 females, 17 males) patients with genetically proven 4H with a median age of 12 years (range: 2-39 years). Six patients (four females, two males) had mutations in POLR3A, the majority, 27, in POLR3B (13 females, 14 males), and 3 in POLR1C (2 females, 1 males). Severity of clinical disease varied widely with GMFCS scores ranging from I (n ¼ 7) to V (n ¼ 2). ►Fig. 2 shows the evolution of BCR and pons diameter in controls and patients. There was no significant difference between males and females. For grading brainstem and supratentorial atrophy in 4H, we pragmatically designed age groups using normal values (►Fig. 2; ►Tables 2 and 3).
In 4H patients, pons diameter was significantly smaller with a mean diameter of 18.38 mm (standard deviation [SD]: 1.98 mm) versus 20.86 mm (SD: 1.89 mm) in controls (p < 0.01). Similarly, BCR was found to be higher in patients with a mean BCR of 0.094 (SD: 0.026) versus 0.071 (SD: 0.015) in controls (p < 0.01). Although this difference was already present in younger patients, it further increased with age, indicating progressive volume loss.
Scoring Disagreement and Interrater Reliability
In the first round, a total of 1,080 scores were collected (27 items scored for 40 MRI scans). For only 48 (4.4%) scores, less than three raters agreed. In one single patient, the maximum number of items with disagreement was 3. After the second assessment of the 48 items with diverging scores, only 3 (0.3%) from the total of 1,080 scores remained without This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited. agreement of at least three raters. We refrained from imposing a consensus score and accepted that no consensus could be reached for these three items.
In the first round, IRR was found to be excellent for all subscores, with ICC values for consistency of 0.84 (95% confidence interval [CI]: 0.76-0.90) for hypomyelination, 0.88 (95% CI: 0.82-0.93) for atrophy, and 0.87 (95% CI: 0.80-0.92) for total MRI score. Overall, IRR was lower for items scored on T1-weighted scans, with some items showing a poor IRR (ICC < 0.40). These items included the periventricular frontoparietal border area, parieto-occipital WM (both subcortical and periventricular), the anterior limb of the internal capsule, and the cerebellar WM. In contrast, all items scored on T2-weighted images showed at least a fair IRR (ICC > 0.40). There was little disagreement on atrophy scores including those scores derived from pons diameter and BCR.
In the second round including the 48 scores with disagreement, results were largely similar. One of the difficult items to score was myelination of the cerebellar WM, especially in patients with severe cerebellar atrophy. We therefore considered o mitting this region from the final score. Analyzing results without this item did not influence overall outcome (not shown), and therefore we decided not to omit it from the scoring, but, to facilitate future use, to slightly modify the system by rating WM signal of the middle cerebellar peduncles instead.
MRI Severity, Hypomyelination, and Atrophy Scores
Median scores were 31/54 (range: 8-45) for total MRI score, 23/44 (range: 7-39) for hypomyelination, and 7/10 (range: 0-10) for atrophy. Scores tended to be higher in females than in males (median 34 vs. 26, respectively, p ¼ 0.024). Total MRI scores did not significantly increase with age (►Fig. 3A). When looking at hypomyelination and atrophy scores separately, only atrophy scores were significantly correlated with age (►Fig. 3B, C). Global MRI and hypomyelination scores were significantly higher for patients with mutations in POLR3A than for patients with mutations in POLR3B, whereas atrophy scores were in the same range (►Fig. 4).
Magnetic Resonance Imaging Scores and Motor Disability
Patients with more limitations in GMF were found to have higher total MRI scores (►Fig. 3D). However, a large variability of MRI scores was seen with all GMFCS levels, Fig. 3 Magnetic resonance imaging (MRI) scores in relation to age and gross motor function. Global MRI score (A) and hypomyelination score (B) do not show significant correlation with age, whereas atrophy is significantly correlated with age (C). All three scores significantly correlate with gross motor function (D-F). Red diamonds, patients with mutations in POLR3A; blue triangles, patients with mutations in POLR3B; green squares, patients with mutations in POLR1C. 
interestingly most pronounced in patients with mild disability. A similar distribution was seen for hypomyelination and atrophy scores when analyzed separately, with increasing scores for more advanced clinical disease (►Fig. 3E, F).
Magnetic Resonance Imaging Scores at Follow-Up
Follow-up MRI examinations were available for four patients with a time interval ranging from 1 to 8 years between scans. Atrophy scores either remained stable (n ¼ 1) or slightly worsened (n ¼ 3). Hypomyelination scores, and therefore total MRI severity scores, improved in three of them. In those patients who showed improvementof hypomyelination scores, GMFCS remained stable (n ¼ 2) or worsened slightly (n ¼ 1).
Discussion
The aim of this study was to develop and validate a MRI scoring system for 4H, assessing hypomyelination and atrophy in this hypomyelinating disease. We decided to score both hypomyelination and atrophy, as cerebellar atrophy is a known early feature of 4H and as supratentorial atrophy slowly progresses with age. The authors of the recently published score for PMD independently also combined atrophy and myelination scores. They included fluid-attenuated inversion recovery (FLAIR) in addition to T1-and T2-weighted images, but omitted measurements to quantify atrophy.
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IRR was found to be excellent for hypomyelination, atrophy, and global MRI severity scores when assessed using ICC statistics. Nevertheless, in the first round, IRR varied between different items of the scoring system, with some items showing poor IRR, particularly those scored on T1-weighted images. Apparently, these items were more difficult to score or more sensitive to rater subjectivity. More precise instructions provided to the raters in the second round resulted in better agreement. As some atrophy items were assessed quantitatively (BCR, 20 pons diameter 21 ), scoring of atrophy may be more objective than in the established scores for X-ALD or MLD. 3,4 BCR was first described as a measure of atrophy in the 1980s and used for a variety of diseases including multiple sclerosis and Alzheimer's disease. 22, 23 Recently, one group used this parameter to measure brain atrophy in PMD. 24 In our patients, brainstem atrophy sets in much earlier than supratentorial atrophy, possibly at least in part due to the early cerebellar atrophy. All MRI severity scores-hypomyelination, atrophy, and global scores-correlated with GMF, supporting the hypothesis that not only degree of hypomyelination but also atrophy codetermines handicap. A recent study on MRI changes in PMD reached similar conclusions, albeit less pronounced for myelination than for atrophy.
5 Also in PMD, another group reported correlation of brain atrophy with disability, though without assessing myelination. 24 In multiple sclerosis, the prototype of acquired WM disease, brain atrophy is at least as important for clinical, especially cognitive impairment as WM lesions. 25, 26 Atrophy, in contrast to hypomyelination scores, clearly increased with age, suggesting age-dependent neuroaxonal loss rather than loss of myelin, although more long-term observations are needed to confirm this finding in larger patient groups. Interestingly, in 4H patients with mild clinical disease, MRI scores differed more widely than in patients with more severe disease, confirming our clinical experience.
In female patients, MRI scores tended to be higher than in male patients; this might be at least in part due to the fact that females were overrepresented in the group of patients with mutations in POLR3A. That in the four patients with follow-up scans there were some changes including improved myelination scores despite stable or slightly deteriorated GMFCS is difficult to interpret due to the small number of follow-up MRIs. Larger studies are needed to study evolution of MRI changes and clinical symptoms over time.
We recently described several patients with atypical forms of 4H, without clear myelin deficit and variable neurologic signs and symptoms. 27 Those patients were not included in this study as we focused on typical patients with hypomyelination, but it will be interesting to know whether significantly more myelin in these atypical cases also means less clinical handicap once enough cases will become available. We were also interested in possible differences between patients with mutations in different genes. Although our Fig. 4 Magnetic resonance imaging scores in relation to mutated gene. Score results (mean and standard error of the mean) depicted for the three patient groups (patients with mutations in POLR3A, POLR3B and POLR1C, respectively). Global (A) and hypomyelination (B) scores significantly differ between patients with POLR3A and POLR3B mutations (Mann-Whitney U test; Ã p < 0.05; ÃÃÃ p < 0.001). Atrophy scores do not show significant differences (C). We did not include the three patients with POLR1C mutations in this analysis as this latter group was very small. Diamonds, patients with mutations in POLR3A; triangles, patients with mutations in POLR3B; squares, patients with mutations in POLR1C.
group consisted mainly of patients with mutations in POLR3B, patients with mutated POLR3A had higher mean MRI severity scores than the other two groups, consistent with the greater clinical severity with POLR3A mutations shown in our study on a large number of patients with 4H.
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One might wonder why, in the times of quantitative imaging and volumetry, we chose a comparably simple approach for this scoring system. It has several benefits: the sequences we used are part of standard protocols and therefore usually available, they can be compared among diverse scanners (with their slightly different protocols), and there is no need for specific control groups. Quantitative methods are more objective than a rater-dependent approach and often depend on specific scanners, making it laborious or even impossible to compare results between different centers or with changing MRI systems in even the same center. A robust, simple method as ours may be used in multicenter studies and also can make use of MRIs collected during a longer period, essential for a rare disease as 4H. These advantages are at the same time the limitations of this study: the use of different scanners with different field strengths and protocols and the retrospective setup may have affected results. That we did find correlations between MRI changes and clinical severity despite these odds, and that these correlations are comparable to other recent MRI studies on PMD, is encouraging and strengthens our interpretation.
In conclusion, this study shows that the proposed MRI scoring system reliably quantifies hypomyelination and atrophy, both correlating with clinical disease severity, in patients with 4H. It is easy to apply, even retrospectively, might serve as a useful biomarker for future studies, and can be used, with small adaptations, for other hypomyelinating disorders. 
